Wednesday, 17 Oct 2018

You are here

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.

COAST-W is a multicenter, randomized, double-blind, placebo-controlled 16-week study of the efficacy and safety of ixekizumab in active AS patients who were TNFi-IR.  Patients were treated with 80 mg of Taltz SC either every two weeks or every four weeks (following a 80 mg or 160 mg starting dose at Week 0), or placebo.  The primary efficacy endpoint was the proportion of patients at 16 weeks who achieved ASAS40 response.

The Taltz development program (COAST) in axial SpA (AS) includes the three different trials COAST-V (bDMARD-naïve), COAST-W (TNFi experienced), and COAST-X (non-radiographic axSpA who are bDMARD-naïve) studies . A long-term extension study will study patients for an additional two years. 

COAST-W trial showed superior (ASAS40) responses at 16 weeks compared to placebo treated patients. The incidence of serious adverse events was similar with Taltz compared with placebo. 

Ixekizumab is currently FDA approved for the treatment of adults with active psoriatic arthritis and adults with moderate-to-severe plaque psoriasis.

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Apremilast Succeeds in Scalp Psoriasis

Celgene has announced results from the phase 3 STYLE study, showing apremilast yielding significant improvement in moderate-to-severe scalp psoriasis. STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive apremilast 30 mg twice daily or placebo for the first 16 weeks.

Does Gender Make a Difference in Axial Spondyloarthritis

Males and females can both be affected by axial spondyloarthritis (axSpA). A recent study shows that while there are some differences and similarities, HLA-B27 and imaging are still pivotal elements for diagnosis of axSpA in both genders.

Complementary Therapies in Psoriasis

A systematic review in Archives of Dermatology suggests that among complementary and alternative medicine (CAM) therapies, the most effective are indigo naturalis, curcumin, dietary modification, meditation, and acupuncture.

It is estimated that  nearly half of patients with psoriasis report they use CAM, although their benefits are unclear in psoriasis.

Biologic Therapies Improve Work Outcomes in Spondyloarthritis

A study from the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBR-AS) shows that biologic use significantly improves work productivity and overall activity impairment.

 

The BSRBR-AS registry analyzed 577 participants who were employed;  28% were started on biological therapy .

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.